The new Lilly facilities—which include a $5 billion API plant near Richmond, Virginia, which was announced in September—are ...

While the China-targeting Biosecure Act failed to pass muster in a key defense spending bill last year, a retooled version of ...

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the ...

Ad agency Imre has filled the vacancy at the top of its organization, poaching Nadine Lafond from Ogilvy Health to serve as ...

A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

Gamida Cell has scored an expansion for Omisirge, with the FDA endorsing the stem cell-based therapy to treat severe aplastic ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. | Returning its stake in ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Amgen is getting the ball rolling on a far-reaching new partnership that’s set to boost its profile in its hometown of ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...